Johnson & Johnson’s most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $145.00 short put and a strike $135.00 long put offers a potential 19.47% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $145.00 by expiration. The full premium credit of $1.63 would be kept by the premium seller. The risk of $8.37 would be incurred if the stock dropped below the $135.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.
The RSI indicator is at 70.64 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Johnson & Johnson’s Late-Stage Trial Of Single Dose COVID-19 Vaccine Fully Enrolled
Fri, 18 Dec 2020 06:45:59 +0000
Johnson & Johnson (NYSE: JNJ) has completed the participant enrollment for the Phase 3 trials of its single-dose COVID-19 vaccine, the company said in a statement Thursday.What Happened: JNJ has enrolled roughly 45,000 participants in the â€œEnsembleâ€ trial, which is being conducted by its Janssen unit.The pharma company expects interim data from the trial by the end of January. It anticipates applying for emergency use authorization with the U.S. Food and Drug Administration in February if the study shows the vaccine to be effective.JNJ said that a separate Phase 3 trial for its investigational Janssen COVID-19 vaccine candidate by Jansen is ongoing to explore a two-dose regimen. Based on an earlier report, the â€œEnsemble 2â€ trial will complete the participants’ recruitment by March.Why It Matters: The â€œEnsembleâ€ trial was paused for a week in October when a participant developed an unexplained illness. JNJ resumed the trial after no clear cause of the illness was found.JNJ vaccine is one of the six vaccines expected to get a regulatory nod by the first quarter, according to Bill Gates. U.S. health officials are also offering logistical support to vaccine makers for the speedy delivery and efficient supply chain as the demand rises.Moderna Inc (NASDAQ: MRNA) secured the nod of the FDA advisory panel for its experimental COVID-19 vaccine on Thursday. The FDA typically concurs with the advisory panel’s recommendations and EUA could arrive on Friday. Moderna’s COVID-19 vaccine would the second such to be available in the United States after Pfizer Inc. (NYSE: PFE) and BioNTech SE’s (NASDAQ: BNTX).Price Action: JNJ shares closed 2.64% higher at $153.62 on Thursday.See more from Benzinga * Click here for options trades from Benzinga * Alphabet-Backed GoCardless Nears B Valuation In Latest Funding Round: CNBC * Robinhood â€˜Does Not Act In Best Investor Interest,’ Massachusetts Securities Watchdog Alleges(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
J&J says late-stage COVID-19 vaccine trial fully enrolled
Fri, 18 Dec 2020 02:49:58 +0000
Johnson & Johnson said on Thursday it has fully enrolled participants for the first late-stage trial of its COVID-19 single-dose vaccine candidate. The study, named Ensemble, has enrolled about 45,000 participants and is being conducted by its unit Janssen, J&J said https://www.jnj.com/our-company/johnson-johnson-announces-its-first-phase-3-covid-19-vaccine-trial-ensemble-is-fully-enrolled in a statement, adding that it expects interim data from the trial by the end of January 2021. J&J also said it plans to submit an emergency use authorization application to the U.S. Food and Drug Administration (FDA) in February if the data from the study is safe and effective.
Stock Market Today: With Eyes Only for Stimulus, Investors Keep Buying
Thu, 17 Dec 2020 21:47:59 +0000
Wall Street kept its sights squarely on the high likelihood of a stimulus bill Thursday, ignoring discouraging jobs and small business data.
A new coalition takes on social justice in medicine
Thu, 17 Dec 2020 17:29:10 +0000
A new organization â€“ the Preparedness and Treatment Equity Coalition â€“ is looking to use data and new metrics to bring more equity to healthcare.
Here’s What You Need to Know Before Buying Coronavirus Vaccine Stocks
Thu, 17 Dec 2020 14:51:00 +0000
If you’re interested in buying coronavirus vaccine stocks, there still are plenty of opportunities. In this Motley Fool Live video recorded on Dec. 11, 2020, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss important factors to consider before you get started. Corinne Cardina: What are three things you think investors should consider before buying a coronavirus vaccine stock?
Follow Us on Facebook